Stanley Laman Group Ltd. Purchases 312 Shares of Bristol-Myers Squibb (NYSE:BMY)

Stanley Laman Group Ltd. increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 5.4% in the fourth quarter, HoldingsChannel reports. The firm owned 6,092 shares of the biopharmaceutical company’s stock after buying an additional 312 shares during the period. Stanley Laman Group Ltd.’s holdings in Bristol-Myers Squibb were worth $313,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. OFI Invest Asset Management bought a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth approximately $25,000. Milestone Investment Advisors LLC bought a new position in Bristol-Myers Squibb during the third quarter worth $27,000. Blue Bell Private Wealth Management LLC raised its position in shares of Bristol-Myers Squibb by 61.5% in the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 200 shares during the period. Legacy Financial Group LLC acquired a new stake in shares of Bristol-Myers Squibb during the 3rd quarter worth about $39,000. Finally, VisionPoint Advisory Group LLC boosted its holdings in shares of Bristol-Myers Squibb by 300.5% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 553 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on BMY. Bank of America cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Redburn Atlantic cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. Barclays decreased their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday. Finally, StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Price Performance

Shares of NYSE:BMY traded up $0.16 during trading on Friday, hitting $44.86. 21,279,666 shares of the company were exchanged, compared to its average volume of 15,968,238. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24. Bristol-Myers Squibb has a 1-year low of $44.34 and a 1-year high of $69.10. The company has a market capitalization of $90.92 billion, a P/E ratio of 11.62, a price-to-earnings-growth ratio of 1.47 and a beta of 0.39. The business’s 50 day moving average is $51.03 and its 200-day moving average is $51.18.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period last year, the firm posted $2.05 earnings per share. Equities analysts forecast that Bristol-Myers Squibb will post 6.63 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be issued a dividend of $0.60 per share. The ex-dividend date is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.35%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 62.18%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.